Merck dangles up to $425 million to team with Flagship’s Foghorn Therapeutics on drugging the shape of DNA

Jason Mast

Editor

Two years after it first emerged from stealth mode, Flagship’s Foghorn Therapeutics has nabbed its first Big Pharma partner as Merck signs on to the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck dangles up to $425 million to team with Flagship’s Foghorn Therapeutics on drugging the shape of DNA

Jason Mast

Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Sofinnova outlines $550M fund after IPOs and M&A deals

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Mer­ck dan­gles up to $425 mil­lion to team with Flag­ship’s Foghorn Ther­a­peu­tics on drug­ging the shape of DNA

Jason Mast

Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Merck dangles up to $425 million to team with Flagship’s Foghorn Therapeutics on drugging the shape of DNA

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Sofinnova outlines $550M fund after IPOs and M&A deals

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.